Why Audit Success No Longer Predicts Clinical-Stage Performance In Biotech

A clean GLP audit or a smooth pre-IND interaction feels like proof of control, yet companies that pass inspections still hit submission delays and longer diligence cycles as programs advance. The cause is readiness fragility, not compliance failure. Between 50 and 200 employees, accelerating clinical programs, CDMO and CRO oversight running on separate documentation tracks, and manual coordination that stops scaling collide. Teams then rebuild traceability by hand before each milestone, and senior QA leaders are pulled off program oversight to do it.

Read the white paper to see what audit results do and do not predict.